Lilly, Boehringer win FDA nod for diabetes med; Watson launches generic Concerta;

@FiercePharma: Would Pfizer break-up leave a healthier core? News | Follow @FiercePharma

> The FDA says it has approved Tradjenta, a new diabetes pill from Boehringer Ingelheim and Eli Lilly, for patients who can't control their blood sugar with older medicines. Report

> Watson Pharmaceuticals said it has started selling an authorized generic version of Johnson & Johnson's attention deficit hyperactivity disorder drug Concerta. News

> Nycomed is considering establishing its own high-tech production in Ukraine and expects to decide by year's end whether to sink €35 million into the project. Story

> Acura Pharmaceuticals named Robert Jones as its interim president and CEO Monday following the death of president and CEO Andrew Reddick last week. Article

> AstraZeneca said Mark Mallon had been appointed as president of AstraZeneca China, effective May 1. Item

> Genzyme and its Cambridge, MA, landlord have won a $1.5 million tax abatement for the company's iconic headquarters building near Kendall Square. Report

> Montana Gov. Brian Schweitzer said he would allow a controversial bill restricting the state's medical-marijuana business to become law without his signature. Article

> Bosch Packaging Technology is planning to expand its position in the pharmaceutical processing equipment sector with the purchase of two of Oystar's business units. Story

> An Abbott Laboratories unit sued generic drugmaker Teva Pharmaceuticals USA for patent infringement with its plans to market a copy of Abbott's AndroGel testosterone preparation. Item

> AstraZeneca said that U.S. regulators approved an injectable version of its heartburn drug Nexium for use in infants as young as a month old. News

Biotech News

 @FierceBiotech:  Teva elbows aside Valeant with $6.8B buyout deal for Cephalon. Item  | Follow @FierceBiotech

 @JohnCFierce: Wilex gets $19 million for U.S. licensing rights to renal cell cancer drug Rencarex. Story | Follow @JohnCFierce

>  Vivus eyes path to a limited approval for obesity drug. Item 

> Next-gen addiction vaccines offer a tough challenge to biotechs. Article 

> Clinical, regulatory jobs top biotech's "must-hire" list. Story 

> Pfizer, Icagen recruit Yale scientists for pain collaboration. Report 

Biotech Research News

> Paralyzed man reports sensations after embryonic stem cell treatment. Article 

> Researchers can erase traumatic memories in snails ... humans next? Item

> Artificial nose can quickly sniff out bacterial infections. Story

> Cancer-fighting compounds found under the sea. News

> Newly discovered genes could lead to earlier glaucoma diagnosis. Report

>  Why was U.S. so sure it had Osama bin Laden's DNA? Story

 Manufacturing News

> Generics makers position for world domination. Story 

> ABC, Cardinal see growth in specialty pharma. Item 

> ISP passes ingredient price hikes on to drugmakers. Article 

> Bayer tweaks anti-counterfeiting tactics. Report 

> Accenture IT fix for quality misses key point. News

And Finally... A study published in the American Journal of Psychiatry suggests that newly depressed patients shouldn't start with two drugs: Combination therapy appeared to be no more effective than a single drug in improving depression symptoms. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.